Lonza vs Richter BioLogics: CDMO Comparison
Side-by-side comparison of Lonza and Richter BioLogics on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Lonza has FDA inspections on record (2); Richter BioLogics does not yet appear in the FDA inspection database.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Richter BioLogics has materially broader EMA GMP coverage (9 active certificates vs 3) — stronger EU footprint.
- Lonza maintains 5 MHRA / UK GMP certificates; Richter BioLogics does not.
On a 13-modality CDMO landscape, both Lonza and Richter BioLogics qualify as Recombinant Proteins manufacturers; Richter BioLogics carries the higher composite Signal Score for Recombinant Proteins programs in this comparison.
What to evaluate for Recombinant Proteins programs
Both Lonza and Richter BioLogics qualify as Recombinant Proteins CDMOs. When choosing between them for Recombinant Proteins programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Expression host & scale
Microbial hosts (E. coli, P. pastoris) suit non-glycosylated proteins; mammalian (CHO) is the workhorse for glycoproteins. Confirm validated bioreactor scale and the CDMO's experience with your target.
Purification & analytics
Downstream complexity (multiple chromatography steps, refolding for E. coli) drives cost and timeline. Ask about the orthogonal analytics package — purity, identity, potency.
Regulatory readiness
Clean FDA 483 history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & commercial readiness
For programs heading to BLA, evaluate validated commercial scale and any approved-product track record.
Frequently asked: Lonza vs Richter BioLogics
Which has the stronger FDA inspection record, Lonza or Richter BioLogics?
Both Lonza and Richter BioLogics maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Lonza has 2 FDA inspections on record; Richter BioLogics has 0.
How do Lonza and Richter BioLogics compare on European GMP coverage?
Lonza holds 3 active EMA GMP certificates and 5 MHRA / UK certificates. Richter BioLogics holds 9 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Lonza or Richter BioLogics?
Lonza is matched to 1 ClinicalTrials.gov record as a manufacturing partner; Richter BioLogics is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for Recombinant Proteins manufacturing — Lonza or Richter BioLogics?
Both Lonza and Richter BioLogics are tagged as Recombinant Proteins CDMOs in our directory, so both are credible options for Recombinant Proteins programs. The most important differentiator for Recombinant Proteins selection is typically expression host & scale: Microbial hosts (E. coli, P. pastoris) suit non-glycosylated proteins; mammalian (CHO) is the workhorse for glycoproteins. Confirm validated bioreactor scale and the CDMO's experience with your target. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Lonza carries a Signal Score of 78/100 and Richter BioLogics carries 83/100 — essentially tied for Richter BioLogics. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →